Chips to Technology Stocks grabbed investors attention. All that and more tonight on nightly Business Report for monday, april 28th. Good evening, everyone. 100 billion. Thats what pfizer is offering to pay for astrazeneca. This is the Second Time Around pfizer is pushing for a deal with its british rival. Investors are cheering. Sending the dow soaring. Shares of pfizer shot up more than 4 by far the biggest gainer in the dow and astrazeneca jumped 12 . While the pharmaceutical deal may be huge its not a done deal. Astrazeneca has already rejected the offer and an earlier approach from pfizer saying the 100 billion cash and stock offer is too low and that it undervalues the company. We took a look at what combining these two companies mean to the pharmaceutical industry and whats at stake for pfizer and astrazeneca. Its the kind of deal that doesnt come around too often. 14 years ago pfizer paid 85 billion to buy warner lambert. That was the Biggest Health care combination ever. And s
Its relied on as a measure of progress, but does it paint an accurate picture . One synthetic number that purports to describe lived reality with an average, has to make choices about what you include, what do you add, what do you exclude, because you cant include everything. Those are just some of the stories were covering on tonights pbs newshour. Major funding for the pbs newshour has been provided by ive been around long enough to recognize the people who are out there owning it. The ones getting involved, staying engaged. They are not afraid to question the path theyre on. Because the one question they never want to ask is, how did i end up here . I started schwab with those people. People who want to take ownership of their investments, like they do in every other aspect of their lives. Supported by the john d. And catherine t. Macarthur foundation. Committed to building a more just, verdant and peaceful world. More information at macfound. Org and with the ongoing support of the
Captioning sponsored by Rose Communications from our studios in new york city, this is charlie rose. Charlie turkey is an important country by any measure. It is a democracy in a troubled region. However, in the eyes of its critics, it is becoming authoritarian and less tolerant. The country is both modern and old, islamic and secular, it has a gdp growth of 4 and look at its geography, i it it is europn and asian, bordered by iran, iraq, syria and others. The syrian refugee crisis has cost turkey billions of dollars. The turkish countrys president is credited with creating turkey as a modern and secular nation. I went to istanbul to visit the Prime Minister. His party was in local elections. He was interested a man to be a bridge in the world and unsuccessful in gaining admission to the European Union. Erdogan today is a source today of some controversy. The Prime Minister is accused of coming down hard on anyone who opposes him. Twitter and youtube have been banned and demonstrators
Chips to Technology Stocks grabbed investors attention. All that and more tonight on nightly Business Report for monday, april 28th. Good evening, everyone. 100 billion. Thats what pfizer is offering to pay for astrazeneca. This is the Second Time Around pfizer is pushing for a deal with its british rival. Investors are cheering. Sending the dow soaring. Shares of pfizer shot up more than 4 by far the biggest gainer in the dow and astrazeneca jumped 12 . While the pharmaceutical deal may be huge its not a done deal. Astrazeneca has already rejected the offer and an earlier approach from pfizer saying the 100 billion cash and stock offer is too low and that it undervalues the company. We took a look at what combining these two companies mean to the pharmaceutical industry and whats at stake for pfizer and astrazeneca. Its the kind of deal that doesnt come around too often. 14 years ago pfizer paid 85 billion to buy warner lambert. That was the Biggest Health care combination ever. And s
Grabbed investors attention. All that and more tonight on nightly Business Report for monday, april 28th. Good evening, everyone. 100 billion. Thats what pfizer is offering to pay for astrazeneca. This is the Second Time Around pfizer is pushing for a deal with its british rival. Investors are cheering. Sending the dow soaring. Shares of pfizer shot up more than 4 by far the biggest gainer in the dow and astrazeneca jumped 12 . While the pharmaceutical deal may be huge its not a done deal. Astrazeneca has already rejected the offer and an earlier approach from pfizer saying the 100 billion cash and stock offer is too low and that it undervalues the company. We took a look at what combining these two companies mean to the pharmaceutical industry and whats at stake for pfizer and astrazeneca. Its the kind of deal that doesnt come around too often. 14 years ago pfizer paid 85 billion to buy warner lambert. That was the Biggest Health care combination ever. And since the recession theres b